FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use
Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:ENPEP-SEC31A

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: ENPEP-SEC31A
FusionPDB ID: 26642
FusionGDB2.0 ID: 26642
HgeneTgene
Gene symbol

ENPEP

SEC31A

Gene ID

2028

22872

Gene nameglutamyl aminopeptidaseSEC31 homolog A, COPII coat complex component
SynonymsAPA|CD249|gp160ABP125|ABP130|HSPC275|HSPC334|NEDSOSB|SEC31L1
Cytomap

4q25

4q21.22

Type of geneprotein-codingprotein-coding
Descriptionglutamyl aminopeptidaseAP-AEAPaminopeptidase Adifferentiation antigen gp160protein transport protein Sec31ASEC31 homolog A, COPII coating complex componentSEC31-like protein 1SEC31-related protein Aweb1-like proteinyeast Sec31p homolog
Modification date2020031320200313
UniProtAcc

Q07075

Main function of 5'-partner protein: FUNCTION: Regulates central hypertension through its calcium-modulated preference to cleave N-terminal acidic residues from peptides such as angiotensin II. {ECO:0000305|PubMed:23888046}.

O94979

Main function of 5'-partner protein: FUNCTION: Component of the coat protein complex II (COPII) which promotes the formation of transport vesicles from the endoplasmic reticulum (ER) (PubMed:10788476). The coat has two main functions, the physical deformation of the endoplasmic reticulum membrane into vesicles and the selection of cargo molecules (By similarity). {ECO:0000250|UniProtKB:Q9Z2Q1, ECO:0000269|PubMed:10788476}.
Ensembl transtripts involved in fusion geneENST idsENST00000265162, ENST00000504100, 
ENST00000436790, ENST00000508479, 
ENST00000264405, ENST00000311785, 
ENST00000326950, ENST00000348405, 
ENST00000355196, ENST00000432794, 
ENST00000443462, ENST00000448323, 
ENST00000500777, ENST00000505472, 
ENST00000505984, ENST00000509142, 
ENST00000513858, ENST00000395310, 
ENST00000508502, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score3 X 3 X 3=2727 X 19 X 11=5643
# samples 328
** MAII scorelog2(3/27*10)=0.15200309344505
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0		log2(28/5643*10)=-4.33296361729939
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: ENPEP [Title/Abstract] AND SEC31A [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: ENPEP [Title/Abstract] AND SEC31A [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)ENPEP(111441522)-SEC31A(83740406), # samples:1
Anticipated loss of major functional domain due to fusion event.ENPEP-SEC31A seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ENPEP-SEC31A seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ENPEP-SEC31A seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ENPEP-SEC31A seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ENPEP-SEC31A seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
ENPEP-SEC31A seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
ENPEP-SEC31A seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneENPEP

GO:0003081

regulation of systemic arterial blood pressure by renin-angiotensin

19608358

HgeneENPEP

GO:0008283

cell proliferation

14998491

HgeneENPEP

GO:0016477

cell migration

14998491

TgeneSEC31A

GO:0051592

response to calcium ion

17196169

TgeneSEC31A

GO:0090110

cargo loading into COPII-coated vesicle

17499046|18843296



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr4:111441522/chr4:83740406)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across ENPEP (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across SEC31A (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000265162ENPEPchr4111441522+ENST00000395310SEC31Achr483740406-266220693242144606
ENST00000265162ENPEPchr4111441522+ENST00000508502SEC31Achr483740406-231220693242144606

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000265162ENST00000395310ENPEPchr4111441522+SEC31Achr483740406-0.0007758520.9992242
ENST00000265162ENST00000508502ENPEPchr4111441522+SEC31Achr483740406-0.0009305680.9990695

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ENPEP-SEC31A

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
ENPEPchr4111441522SEC31Achr4837404062069573ITQKRFLLDPRANPSQPPSDLGFHQQ

Top

Potential FusionNeoAntigen Information of ENPEP-SEC31A in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ENPEP-SEC31A_111441522_83740406.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B35:08NPSQPPSDL0.91630.71111221
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B35:01NPSQPPSDL0.88740.77741221
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B35:03NPSQPPSDL0.88340.75071221
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B35:04NPSQPPSDL0.72780.87111221
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B35:02NPSQPPSDL0.72780.87111221
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B14:03NPSQPPSDL0.79050.7781221
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B35:12NPSQPPSDL0.72780.87111221
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B39:10NPSQPPSDL0.54790.89091221
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B42:02NPSQPPSDL0.37680.54191221
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B42:01NPSQPPSDL0.31830.54191221
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B07:12ANPSQPPSDL0.80280.56251121
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B42:01ANPSQPPSDL0.54860.62761121
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B07:12RANPSQPPSDL0.99850.68041021
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B07:04RANPSQPPSDL0.99530.5081021
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B42:01RANPSQPPSDL0.90070.60971021
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B35:77NPSQPPSDL0.88740.77741221
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B35:23NPSQPPSDL0.88290.79021221
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B35:13NPSQPPSDL0.84960.76051221
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B35:11NPSQPPSDL0.81660.86231221
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B35:09NPSQPPSDL0.72780.87111221
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B35:24NPSQPPSDL0.59760.78461221
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B67:01NPSQPPSDL0.55440.65051221
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B08:12NPSQPPSDL0.3060.69651221
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B67:01ANPSQPPSDL0.70050.73321121
ENPEP-SEC31Achr4111441522chr4837404062069HLA-B67:01RANPSQPPSDL0.96490.7561021

Top

Potential FusionNeoAntigen Information of ENPEP-SEC31A in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ENPEP-SEC31A_111441522_83740406.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-0305QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-0305TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-0305KRFLLDPRANPSQPP318
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-0305ITQKRFLLDPRANPS015
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-0340QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-0340TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-0340ITQKRFLLDPRANPS015
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-0340KRFLLDPRANPSQPP318
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-0466QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-0466TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-0466KRFLLDPRANPSQPP318
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-0466ITQKRFLLDPRANPS015
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-0840QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-0840TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1153QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1153TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1153ITQKRFLLDPRANPS015
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1153KRFLLDPRANPSQPP318
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1169QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1173QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1173TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1179QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1179TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1179ITQKRFLLDPRANPS015
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1179KRFLLDPRANPSQPP318
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1182QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1193QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1193TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1303QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1303TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-13101QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-13101TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1310QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1310TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1333QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1333TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1333ITQKRFLLDPRANPS015
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1333KRFLLDPRANPSQPP318
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1336QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1337QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1337TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1337KRFLLDPRANPSQPP318
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1337ITQKRFLLDPRANPS015
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1338QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1341QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1360QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1365QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1366QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1366TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1385QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1385TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1386QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1388QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1388TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1390QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1390TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1395QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1395TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1402QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1402TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1409QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1409TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1409ITQKRFLLDPRANPS015
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1409KRFLLDPRANPSQPP318
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1413QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1413TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1414QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1419QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1419TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1419KRFLLDPRANPSQPP318
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1419ITQKRFLLDPRANPS015
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1424QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1430QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1430TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1436QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1441QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1441TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1444QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1447QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1447TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1449QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1451QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1451TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1469QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1489QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1494QKRFLLDPRANPSQP217
ENPEP-SEC31Achr4111441522chr4837404062069DRB1-1494TQKRFLLDPRANPSQ116
ENPEP-SEC31Achr4111441522chr4837404062069DRB3-0114QKRFLLDPRANPSQP217

Top

Fusion breakpoint peptide structures of ENPEP-SEC31A

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
5204LLDPRANPSQPPSDENPEPSEC31Achr4111441522chr4837404062069

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ENPEP-SEC31A

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN5204LLDPRANPSQPPSD-6.88559-8.03529
HLA-B14:023BVN5204LLDPRANPSQPPSD-6.02667-8.12017
HLA-B14:023BVN5204LLDPRANPSQPPSD-5.7917-6.012
HLA-B14:023BVN5204LLDPRANPSQPPSD-5.78197-6.00227
HLA-B14:023BVN5204LLDPRANPSQPPSD-5.73538-6.91018
HLA-B14:023BVN5204LLDPRANPSQPPSD-5.43719-6.61199
HLA-B14:023BVN5204LLDPRANPSQPPSD-5.19861-7.29211
HLA-B14:023BVN5204LLDPRANPSQPPSD-3.55597-4.70567
HLA-B52:013W395204LLDPRANPSQPPSD-7.82091-8.04121
HLA-B52:013W395204LLDPRANPSQPPSD-7.13561-8.31041
HLA-B52:013W395204LLDPRANPSQPPSD-5.64226-5.86256
HLA-B52:013W395204LLDPRANPSQPPSD-5.06924-6.24404
HLA-B52:013W395204LLDPRANPSQPPSD-4.15762-5.30732
HLA-B52:013W395204LLDPRANPSQPPSD-3.53995-5.63345
HLA-B52:013W395204LLDPRANPSQPPSD-3.44866-4.59836
HLA-B52:013W395204LLDPRANPSQPPSD-2.4261-4.5196
HLA-A11:014UQ25204LLDPRANPSQPPSD-8.26887-9.44367
HLA-A11:014UQ25204LLDPRANPSQPPSD-7.70462-7.92492
HLA-A11:014UQ25204LLDPRANPSQPPSD-7.37167-7.59197
HLA-A11:014UQ25204LLDPRANPSQPPSD-5.90401-7.05371
HLA-A11:014UQ25204LLDPRANPSQPPSD-5.85242-7.00212
HLA-A11:014UQ25204LLDPRANPSQPPSD-3.08067-5.17417
HLA-A24:025HGA5204LLDPRANPSQPPSD-7.51731-7.73761
HLA-A24:025HGA5204LLDPRANPSQPPSD-7.43005-7.65035
HLA-A24:025HGA5204LLDPRANPSQPPSD-6.9756-9.0691
HLA-A24:025HGA5204LLDPRANPSQPPSD-6.84751-8.02231
HLA-A24:025HGA5204LLDPRANPSQPPSD-6.5707-7.7455
HLA-A24:025HGA5204LLDPRANPSQPPSD-4.75464-6.84814
HLA-A24:025HGA5204LLDPRANPSQPPSD-4.4795-5.6292
HLA-A24:025HGA5204LLDPRANPSQPPSD-3.7751-4.9248
HLA-B27:056PYJ5204LLDPRANPSQPPSD-5.91542-7.06512
HLA-B27:056PYJ5204LLDPRANPSQPPSD-4.90404-5.12434
HLA-B27:056PYJ5204LLDPRANPSQPPSD-4.09094-4.31124
HLA-B44:053DX85204LLDPRANPSQPPSD-7.2975-7.5178
HLA-B44:053DX85204LLDPRANPSQPPSD-5.97378-7.14858
HLA-B44:053DX85204LLDPRANPSQPPSD-5.95259-6.17289
HLA-B44:053DX85204LLDPRANPSQPPSD-5.4629-6.6377
HLA-B44:053DX85204LLDPRANPSQPPSD-4.25278-6.34628
HLA-B44:053DX85204LLDPRANPSQPPSD-3.99841-5.14811
HLA-B44:053DX85204LLDPRANPSQPPSD-3.98019-6.07369
HLA-B44:053DX85204LLDPRANPSQPPSD-2.99966-4.14936
HLA-A02:016TDR5204LLDPRANPSQPPSD-3.7347-4.9095
HLA-A02:016TDR5204LLDPRANPSQPPSD-3.56342-4.71312
HLA-A02:016TDR5204LLDPRANPSQPPSD-2.66431-2.88461

Top

Vaccine Design for the FusionNeoAntigens of ENPEP-SEC31A

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
ENPEP-SEC31Achr4111441522chr4837404061021RANPSQPPSDLAGATCTTGGCTTTCACCAACAATCACCAGTGGT
ENPEP-SEC31Achr4111441522chr4837404061121ANPSQPPSDLTCTTGGCTTTCACCAACAATCACCAGTGGT
ENPEP-SEC31Achr4111441522chr4837404061221NPSQPPSDLTGGCTTTCACCAACAATCACCAGTGGT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
ENPEP-SEC31Achr4111441522chr483740406015ITQKRFLLDPRANPSCCCAAGAGCTAACCCTTCTCAGCCCCCTTCAGATCTTGGCTTTCA
ENPEP-SEC31Achr4111441522chr483740406116TQKRFLLDPRANPSQAAGAGCTAACCCTTCTCAGCCCCCTTCAGATCTTGGCTTTCACCA
ENPEP-SEC31Achr4111441522chr483740406217QKRFLLDPRANPSQPAGCTAACCCTTCTCAGCCCCCTTCAGATCTTGGCTTTCACCAACA
ENPEP-SEC31Achr4111441522chr483740406318KRFLLDPRANPSQPPTAACCCTTCTCAGCCCCCTTCAGATCTTGGCTTTCACCAACAATC

Top

Information of the samples that have these potential fusion neoantigens of ENPEP-SEC31A

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
KIRCENPEP-SEC31Achr4111441522ENST00000265162chr483740406ENST00000395310TCGA-B0-4691-01A

Top

Potential target of CAR-T therapy development for ENPEP-SEC31A

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneENPEPchr4:111441522chr4:83740406ENST00000265162+102019_39575958.0TransmembraneHelical%3B Signal-anchor for type II membrane protein

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to ENPEP-SEC31A

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to ENPEP-SEC31A

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
TgeneSEC31AC0079744Diffuse Large B-Cell Lymphoma1CTD_human